The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Postmortem evaluation of end-organ toxicity in patients with glioblastoma (GBM) treated with temozolomide (TMZ) and bevacizumab (BEV).
J. Zhu
No relevant relationships to disclose
X. J. Tian
No relevant relationships to disclose
N. Linendoll
No relevant relationships to disclose
R. Pfannl
No relevant relationships to disclose
M. Pilichowska
No relevant relationships to disclose